We aimed to determine if these two recurrence-associated MAPK1 mutations may also confer erlotinib sensitivity in HNSCC as reported for MAPK1p.E322K (refs 6,7). This evidence concerns the gene MAPK1 and head and neck squamous cell carcinoma.